IMMA

What IMMA does

IMMA (Imma Health) is an Israel-based medical device company developing an at-home ovarian stimulation monitoring system for women undergoing IVF treatment. Founded in 2021 and headquartered in Modi'in-Maccabim-Re'ut with 1-10 employees, the company targets a specific bottleneck in the IVF workflow: the 8-12 day ovarian stimulation window during which patients typically must make repeated clinic visits for transvaginal follicle monitoring. IMMA's solution replaces most of these visits with at-home self-monitoring.

The product is a four-component integrated platform: (1) the IMMA Probe, an ultraportable, manipulation-free ultrasound probe designed for non-expert home use that automatically acquires a large image volume in a short time; (2) ultrafast ultrasound imaging technology with patents pending on signal processing; (3) Sono Markers, a proprietary AI image analysis engine with six defined levels of analysis that performs automated plane selection and volume reconstitution to generate clinical-grade reports; and (4) a dedicated mobile application that transmits imaging and analysis results to the prescribing physician for remote review. The device is physician-prescribed and distributed through IVF clinics and reproductive endocrinology centers.

IMMA's business model is hardware-led with a recurring software and consumables tail. Revenue streams include probe hardware sales, AI-powered analysis services delivered through the mobile app, and recurring consumables for the contact pressure component. The go-to-market is enterprise field sales targeting IVF clinics and fertility specialists, supported by a Medical Advisory Board with KOLs from Hadassah, CCRM NYC, Sheba Tel Hashomer, Boston IVF, Massachusetts General Hospital, the American Hospital of Paris, and UZ Gent. To date the company has raised approximately $4.1 million across a $1.6M Israel Innovation Authority grant and a $2.5M IXcore-led equity round in August-September 2025, plus the EIC Seal of Excellence (2024) and multiple competition wins. The company has signaled a longer-term platform ambition to extend the probe-plus-AI architecture into broader women's health use cases including PCOS, endometriosis, pregnancy monitoring, and menopause management.

Name

IMMA

Legal name

Imma Health

Website

https://imma.health

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

IMMA (Imma Health) is an Israel-based medical device company that has developed an at-home ovarian stimulation monitoring system for women undergoing IVF, combining a manipulation-free ultrasound probe, AI-powered image analysis, and a mobile app for physician-prescribed remote follicle monitoring.

Ownership category

akta.pro rank

Product category

Fertility Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)

akta.pro secondary industries

Women’s Health & Fertility Tracking Devices (Ovulation/Temp Sensors, Pelvic Health Devices) (CRACAQAJ), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

Keywords

• Fertility monitoring devices
• At-home ultrasound
• IVF medical devices
• AI ultrasound imaging
• Women's health technology

Headquarters

HQ city

Ra'anana

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Hardware Device Sales: Sale of the ultraportable at-home ultrasound probe device for ovarian stimulation monitoring.
2. AI-Powered Analysis Services: Automated AI image analysis capabilities as part of the monitoring solution.
3. Mobile Application Platform: Dedicated app providing communication between patients and medical teams, likely offered as a subscription or included with device purchase.
4. Consumables: Contact pressure consumables required for the ultrasound procedure.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

IMMA develops and sells an at-home ovarian stimulation monitoring system for women undergoing IVF treatment. The system integrates a manipulation-free ultraportable ultrasound probe, AI-powered automated image analysis (Sono Markers), and a dedicated mobile application that connects patients to their medical team. It enables women to perform follicle follow-up scans at home during the 8-12 day stimulation period, reducing the need for in-clinic visits while preserving clinical-quality monitoring.

Product overview

IMMA offers a unified at-home ovarian stimulation monitoring platform for IVF treatment. The system consists of four integrated components: (1) the IMMA Probe, an ultraportable manipulation-free ultrasound device for at-home use; (2) ultrafast ultrasound imaging technology; (3) AI-powered Sono Markers for automated image analysis; and (4) a dedicated mobile application for patient-physician communication. Together, these components enable women to perform follicle monitoring at home, reducing clinic visits while maintaining clinical-quality monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

• IMMA At-Home Ovarian Stimulation Monitoring System

Quantifiable outcome

• Reduces number of clinic visits during ovarian stimulation monitoring
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mira: Mira sells at-home hormone and ovulation tracking devices and apps for women trying to conceive. It is comparable to IMMA as a direct-to-consumer/at-home fertility monitoring hardware + software company targeting the same patient population, although Mira focuses on hormonal metrics rather than ultrasound imaging.
• Natural Cycles: Natural Cycles is an FDA-cleared digital platform for fertility and cycle tracking, combining a wearable/measurement device with a software application. It is comparable to IMMA in offering regulated, app-driven at-home reproductive health monitoring with a subscription revenue model.
• Inito: Inito makes an at-home fertility monitor that measures multiple hormones via urine test strips read by a connected device. Comparable to IMMA as a connected at-home fertility diagnostic device targeting women undergoing or planning conception.
• Elvie: Elvie develops connected women's health hardware (e.g., pelvic floor trainers, breast pumps) paired with mobile apps. Comparable to IMMA in combining a consumer-grade connected device with a women's health mobile experience, and in targeting the same broader category of at-home female health monitoring.

Emerging players

• Modern Fertility (Ro): Modern Fertility offers at-home hormone testing and digital tools for women's reproductive health, now part of Ro. Comparable to IMMA in addressing fertility-related diagnostics through a consumer-friendly at-home + telehealth model, though focused on blood-based hormone testing rather than imaging.
• Kindbody: Kindbody operates fertility clinics and a digital platform for women's reproductive health, including employer-sponsored fertility benefits. Comparable to IMMA as a fertility-focused women's health provider, and a potential B2B partner or competitor in the IVF monitoring workflow.

Broad incumbents

• Maven Clinic: Maven Clinic is a large virtual women's and family health platform serving employers and payers, including fertility, pregnancy, and postpartum care. Comparable to IMMA in addressing the same patient journey with a tech-enabled, remote-monitoring approach, but as a broad incumbent rather than a hardware specialist.
• Progyny: Progyny is a leading fertility benefits management company serving large US employers, providing managed fertility care through a network of clinics. Comparable to IMMA as a stakeholder in the US fertility ecosystem and a potential payer-side channel for IMMA's home monitoring solution.
• Butterfly Network: Butterfly Network manufactures handheld, AI-enabled ultrasound probes for point-of-care use across multiple clinical specialties. Comparable to IMMA in handheld ultrasound + AI architecture and the underlying regulatory pathway, though Butterfly focuses on clinician use rather than patient-administered home scanning.
• Exo Imaging: Exo Imaging is a handheld ultrasound + AI platform targeting clinical point-of-care applications. Comparable to IMMA in the combined hardware/AI ultrasound space, though oriented toward professional clinical users rather than direct-to-patient at-home fertility monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/imma-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMMA